Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus XELOX in first-line gastric cancer
NCT03745170Phase 3Completed
- Sponsor
- Innovent Biologics
- Start
- Dec 2018
- Primary completion
- Jun 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of sintilimab in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by Innovent Biologics. Started Dec 2018; status: completed.
02
Drugs
sintilimab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT03745170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03745170.